Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Multiple thoughts.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5861)
•••
Comment by Noteableon Jun 18, 2024 12:30pm
33 Views
Post# 36094159

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Multiple thoughts.

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Multiple thoughts.Revelations of Trump campaign connections to Russia were documented in the Steele dossier. The dossier is composed of a batch of short reports produced between June and December 2016 by Orbis Business Intelligence, a London-based firm specializing in commercial intelligence for government and private-sector clients.

Steele was the president of the Cambridge Union, and was a career British intelligence officer with service in Moscow, Paris, and Afghanistan prior to work as the head of the Russia desk at British intelligence HQS. While in London he worked as the personal handler of Russian defector Alexander Litvinenko. He was a respected professional who had success in some of the most difficult intelligence environments. He retired from SIS in 2009 and started Orbis Business Intelligence along with a former colleague. Prior to his work on the Russian dossier for Orbis, he was best-known for his investigation of the world soccer association FIFA, which provided direct support to the FBI’s successful corruption case. Steele and Orbis were also known for assisting various European countries in understanding Russian efforts to meddle in their affairs.

https://slate.com/news-and-politics/2017/09/a-lot-of-the-steele-dossier-has-since-been-corroborated.html
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities